Cytokinetics Says European Regulator Validated Its Application for Cardiomyopathy Drug Candidate

MT NewswiresDec 23 21:03

Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating

Futu NewsDec 23 20:31 · Ratings

Express News | Cytokinetics Inc - FDA Sets Pdufa Target Action Date for Aficamten Nda as Sept 26, 2025

BreakingsDec 23 20:30

Express News | Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

BreakingsDec 23 20:30

Truist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)

TipRanksDec 23 20:15 · Ratings

Why Cytokinetics Stock Was a Nearly 5% Winner Today

Yahoo FinanceDec 21 06:25